The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years - Abstract

To investigate the appropriate cut-off level of PSA or other clinical parameters at aged ≤ 50 years.

The rate of detection of PCa in young men will continue to rise associated with the advancement of the current and evolving practices of screening and detection. In this study, we determined whether to investigate the appropriate cut-off level of PSA or other clinical parameters at aged ≤ 50 years. The study population included 106 patients aged ≤ 50 years who had prostate biopsy at our institute. The differences of clinical variables including various PSA related parameters between the patients with significant PCa and insignificant PCa were analyzed. Receiver operating characteristics (ROC) curves and the corresponding areas under the ROC curves (AUC) were calculated. There were no significant differences between no-PCa and PCa patients regarding PSA value, prostate volume (P vol), PSA density (PSAD), transition zone volume (TZ vol), PSATZ density (PSATZD). When the patients meeting the following criteria, Gleason score was ≤ 6 with less than 2 positive biopsy cores, were classified as having insignificant prostate cancer, PSAD could become a useful predictor of significant PCa in men. The AUC was significantly greater in PSAD (0.801) than for the other parameters. The sensitivity and specificity of a PSAD threshold of 0.32 were 85.7% and 77.8%, respectively. In conclusion, PSAD can be a useful and very effective predictor in a man aged ≤ 50 and we can counsel patients with discretion regarding the likelihood of significant PCa.

Written by:
Kosaka T, Mizuno R, Shinojima T, Miyajima A, Kikuchi E, Tanaka N, Shinoda K, Morita S, Mikami S, Oya M.   Are you the author?
Department of Urology, Keio University School of Medicine Tokyo, Japan; Department of Pathology, Keio University School of Medicine Tokyo, Japan.

Reference: Am J Clin Exp Urol. 2014 Dec 25;2(4):332-6.


PubMed Abstract
PMID: 25606579

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe